EMA Authorised: Rxulti (brexpiprazole) — Otsuka Pharmaceutical Netherlands B.V.

View source ↗

Summary

Brexpiprazole (Rxulti) has been authorised in the EU for schizophrenia, with Otsuka Pharmaceutical Netherlands B.V. as the marketing authorisation holder.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Schizophrenia

Drugs mentioned

• RXULTI (brexpiprazole)

Snippet

Status: Authorised. Therapeutic area: Schizophrenia. MAH: Otsuka Pharmaceutical Netherlands B.V.. Decision date: 09/07/2026